Cancer diagnostic classifiers based on quantitative DNA methylation

Expert Review of Molecular Diagnostics

Volumn 14, Issue 3, 2014, Pages 293-305

  Lorincz, Attila T ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

cancer biomarkers; diagnostics; DNA methylation; epigenetics; epigenomics; prognosis; validation

Indexed keywords

CYTOSINE; DNA; TUMOR MARKER; VIRUS DNA;

AREA UNDER THE CURVE; BIOINFORMATICS; BLADDER CANCER; BREAST CANCER; CANCER DIAGNOSIS; CANCER PROGNOSIS; CARCINOGENESIS; COLON CANCER; CPG ISLAND; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DNA METHYLATION ASSAY; EPIGENETICS; GENE EXPRESSION; GENETIC DIFFERENCE; HUMAN; HUMAN GENOME; LUNG CANCER; NONHUMAN; PREDICTIVE VALUE; PROSTATE CANCER; QUANTITATIVE ASSAY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY AND SPECIFICITY; STOMACH CANCER; SYSTEMATIC REVIEW (TOPIC); UTERINE CERVIX CANCER; VIRUS GENOME; WART VIRUS;

DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; HUMANS; MALE; PROSTATIC NEOPLASMS; SEQUENCE ANALYSIS, DNA; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 84896990832     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.2014.897610     Document Type: Review

References (89)

1. Denis H, Ndlovu MN, Fuks F. Regulation of mammalian DNA methyltransferases: a route to new mechanisms. EMBO Rep 2011;12:647-56
2. Lorincz AT. The promise and the problems of epigenetics biomarkers in cancer. Expert Opin Med Diagn 2011;5:375-9
3. Illingworth RS, Bird AP. CpG islands - "a rough guide". FEBS Lett 2009;583:1713-20
4. Laird PW. Principles and challenges of genome-wide DNA methylation analysis. Nature Rev Genet 2010;11:191-203
5. Liu S, Wang J, Su Y, et al. Quantitative assessment of Tet-induced oxidation products of 5-methylcytosine in cellular and tissue DNA. Nucleic Acids Res 2013;41: 6421-9
6. Kim JH, Dhanasekaran SM, Prensner JR, et al. Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer. Genome Res 2011;21:1028-41
7. Vasiljevic N, Ahmad AS, Wu K, et al. Evaluation of diagnostic and prognostic potential of heat shock gene HSPB1 DNA methylation in prostate cancer. Prost Cance Prost Dis 2013;16: 35-40
8. Bert SA, Robinson MD, Strbenac D, et al. Regional activation of the cancer genome by long-range epigenetic remodelling. Cancer Cell 2013;23:9-22
9. Heyn H, Carmona FJ, Gomez A, et al. DNA methylation profiling in breast cancer discordant identical twins identifies DOK7 as a novel epigenetic biomarker. Carcinogenesis 2013;34:102-8
10. Mirabello L, Schiffman M, Ghosh A, et al. Elevated methylation of HPV16 DNA indicates increased risk for the development of high grade cervical intraepithelial neoplasia. Int J Cancer 2013;132:1412-22
11. Hughes LAE, Melotte V, Schrijver J, et al. The CpG island methylator phenotype: whats in a name. Cancer Res 2013;73: 5858-68
12. Cao R, Wang L, Wang H, et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 2002;98: 1039-43
13. Jansson MD, Lund AH. MicroRNA and cancer. Mol Oncol 2012;6:590-610
14. International Agency for Research on Cancer, World Health Organization. GLOBOCAN. 2012. Available from: http:// globocan.iarc.fr/factsheets/cancers
15. Cuzick J, Arbyn M, Sankaranarayanan R, et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 2008;26(Suppl 10):K29-41
16. Cuzick J, Bergeron C, von Knebel Doeberitz M, et al. New technologies and procedures for cervical cancer screening. Vaccine 2012;30(Suppl 5): F107-16
17. Naucler P, Ryd W, Tornberg S, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007;357(16):1589-97
18. Rijkaart DC, Berkhof J, Rozendaal L, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol 2012;13(1): 78-88
19. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010;11(3):249-57
20. Dillner J, Rebolj M, Birembaut P, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008;337:a1754
21. Ronco G, Dillner J, Elfstrom MK, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 2014;383(9916): 524-32
22. Lazcano-Ponce E, Lorincz AT, Cruz-Valdes A, et al. Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial. Lancet 2011;378:1868-73
23. Szarewski A, Mesher D, Cadman L, et al. Comparison of seven tests for high-grade cervical intraepithelial neoplasia in women with abnormal smears: the Predictors 2 study. J Clin Microbiol 2012;50:1867-73
24. Lorincz AT, Castanon A, Lim A, Sasieni P. New strategies for papillomavirus-based cervical screening. Womens Health 2013;9: 443-52
25. Carozzi F, Gillio-Tos A, Confortini M, et al. Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial. Lancet Oncol 2013;14(2): 168-76
26. Burnett ST, Sleeman J. Uneven distribution of methylation sites within the human papillomavirus 1a genome: possible relevance to viral gene expression. Nucleic Acids Res 1984;12:8847-60
27. Lorincz AT, Brentnall AR, Vasiljevic N, et al. HPV16 L1 and L2 DNA methylation predicts high grade cervical intraepithelial neoplasia in women with mildly abnormal cervical cytology. Int J Cancer 2013;133: 637-44
28. Kalantari M, Calleja-Macias IE, Tewari D, et al. Conserved methylation patterns of human papillomavirus type 16 DNA in asymptomatic infection and cervical neoplasia. J Virol 2004;78:12762-72
29. Badal S, Badal V, Calleja-Macias IE, et al. The human papillomavirus-18 genome is efficiently targeted by cellular DNA methylation. Virology 2004;324:483-92
30. Brandsma JL, Sun Y, Lizardi PM, et al. Distinct human papillomavirus type 16 methylomes in cervical cells at different stages of premalignancy. Virology 2009;389:100-7
31. Clarke MA, Wentzensen N, Mirabello L, et al. Human papillomavirus DNA methylation as a potential biomarker for cervical cancer. Cancer Epidemiol Biomarkers Prev 2012;21:2125-37
32. Kalantari M, Osann K, Galleja-Macias IE, et al. Methylation of human papillomavirus 16, 18, 31 and 45 L1 and L2 genes and the cellular DAPK gene: considerations for use as biomarkers of the progression of cervical neoplasia. Virology 2014;448:314-21
33. Wentzensen N, Sun C, Ghosh A, et al. Methylation of HPV18, HPV31, and HPV45 genomes and cervical intraepithelial neoplasia grade 3. J Natl Cancer Inst 2012;104:1738-49
34. Bryant D, Tristram A, Liloglou T, et al. Quantitative measurement of human papillomavirus type 16 L1/ L2 DNA methylation correlates with cervical disease grade. J Clin Virol 2014; 59(1):24-9
35. Oka N, Kajita M, Nishimura R, et al. L1 gene methylation in high risk human papillomaviruses for the prognosis of cervical intraepithelial neoplasia. Int J Gynecol Cancer 2012;23:235-43
36. Bosch FX, Lorincz A, Munoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-65
37. Vasiljevic N, Scibior-Bentkowska D, Brentnall A, et al. A comparison of methylation levels in HPV18, HPV31 and HPV33 genomes reveals similar associations with cervical precancers. J Clin Virol 2014; 59(3):161-6
38. Murakami I, Fujii T, Katsuaki D, et al. Methylation of human papillomavirus-52 and -58 is a candidate biomarker in cervical neoplasia. J Clin Virol 2013;58:149-54
39. Chaiwongkot A, Vinokurova S, Pientong C, et al. Differential methylation of E2 binding sites in episomal and integrated HPV16 genomes in preinvasive and invasive cervical lesions. Int J Cancer 2013;132:2087-94
40. Cheung JLK, Cheung TH, Yu MY, Chan PKS. Virological characteristics of cervical cancers carrying pure episomal form of HPV16 genome. Gynecol Oncol 2013;131:374-9
41. Jacquin E, Baraquin A, Ramanah R, et al. Methylation of human papillomavirus type 16 CpG sites at E2-binding site 1 (E2BS1), E2BS2, and the Sp1-binding site in cervical cancer samples as determined by high-resolution melting analysis-PCR. J Clin Microbiol 2013;51:3207-15
42. Wentzensen N, Sherman ME, Schiffman M, Wang SS. Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the science. Gynecol Oncol 2009;112:293-9
43. Overmeer RM, Louwers JA, Meijer CJ, et al. Combined CADM1 and MAL promoter methylation analysis to detect premalignant cervical lesions in high-risk HPV-positive women. Int J Cancer 2010;129:2218-25
44. Hesselink AT, Heideman DA, Steenbergen RD, et al. Combined promoter methylation analysis of CADM1 and MAL: an objective triage tool for high-risk human papillomavirus DNA-positive women. Clin Cancer Res 2011;17:2459-65
45. Eijsink JJ, Lendvai A, Deregowski V, et al. A four-gene methylation marker panel as triage test in high-risk human papillomavirus positive patients. Int J Cancer 2012;130:1861-9
46. Lai HC, Lin YW, Huang RL, et al. Quantitative DNA methylation analysis detects cervical intraepithelial neoplasms type 3 and worse. Cancer 2010;116: 4266-74
47. Brebi P, Maldonado L, Noordhuis MG, et al. Genome-wide methylation profiling reveals Zinc finger protein 516 (ZNF516) and FK-506-binding protein 6 (FKBP6) promoters frequently methylated in cervical neoplasia, associated with HPV status and ethnicity in a Chilean population. Epigenetics 2013;9(2):308-17
48. Vidal AC, Henry NM, Murphy SK, et al. PEG1/MEST and IGF2 DNA methylation in CIN and cervical cancer. Clin Transl Oncol 2013;16(3):266-72
49. Brentnall AR, Vasiljevic N, Scibior-Bentkowska D, et al. A human gene and HPV DNA methylation classifier for cervical pre-cancer. Int J Cancer 2014. [Epub ahead of print]
50. Stamey TA, Yang N, Hay AR, et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317(15):909-16
51. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360(13):1320-8
52. Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012;367(3):203-13
53. Hessels D, Verhaegh GW, Schalken JA, Witjes JA. Applicability of biomarkers in the early diagnosis of prostate cancer. Expert Rev Mol Diagn 2004;4:513-26
54. Mehra R, Tomlins SA, Yu J, et al. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res 2008;68:3584-90
55. Berney DM, Gopalan A, Kudahetti S, et al. Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study. Br J Cancer 2009;100:888-93
56. Cuzick J, Swanson GP, Fisher G, et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol 2011;12:245-55
57. Lee WH, Morton RA, Epstein JI, et al. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci USA 1994;91:11733-7
58. Kwabi-Addo B, Chung W, Shen L, et al. Age-related DNA methylation changes in normal human prostate tissues. Clin Cancer Res 2007;13:3796-802
59. Bastian PJ, Ellinger J, Wellmann A, et al. Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci. Clin Cancer Res 2005;11:4097-106
60. Maruyama R, Toyooka S, Toyooka KO, et al. Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res 2002;8:514-19
61. Yegnasubramanian S, Kowalski J, Gonzalgo ML, et al. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 2004;64:1975-86
62. Yamanaka M, Watanabe M, Yamada Y, et al. Altered methylation of multiple genes in carcinogenesis of the prostate. Int J Cancer 2003;106:382-7
63. Jeronimo C, Henrique R, Hoque MO, et al. A quantitative promoter methylation profile of prostate cancer. Clin Cancer Res 2004;10:8472-8
64. Vanaja DK, Ballman KV, Morlan BW, et al. PDLIM4 repression by hypermethylation as a potential biomarker for prostate cancer. Clin Cancer Res 2006;12:1128-36
65. Rosenbaum E, Hoque MO, Cohen Y, et al. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy. Clin Cancer Res 2005;11:8321-5
66. Cho NY, Kim BH, Choi M, et al. Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features. J Pathol 2007;211:269-77
67. Nelson WG, De Marzo AM, Yegnasubramanian S. Epigenetic alterations in human prostate cancers. Endocrinology 2009;150:3991-4002
68. Krop I, Player A, Tablante A, et al. Frequent HIN-1 promoter methylation and lack of expression in multiple human tumor types. Mol Cancer Res 2004;2:489-94
69. Vasiljevic N, Wu K, Brentnall A, et al. Absolute quantitation of DNA methylation of 28 candidate genes in prostate cancer using pyrosequencing. Dis Markers 2011;30:151-61
70. Egevad L, Ahmad AS, Algaba F, et al. Standardization of Gleason grading among 337 European pathologists. Histopathology 2013;62(2):247-56
71. Nelson WG, Yegnasubramanian S, Agoston AT, et al. Abnormal DNA methylation, epigenetics, and prostate cancer. Front Biosci 2007;12:4254-66
72. Cuzick J, Fisher G, Kattan MW, et al. Long-term outcome among men with conservatively treated localised prostate cancer. Br J Cancer 2006;95:1186-94
73. Vasiljevic N, Ahmad AS, Thorat MA, et al. DNA methylation gene-based models indicating independent poor outcome in prostate cancer. BMC Cancer 2014; In press
74. Vinarskaja A, Schulz WA, Ingenwerth M, et al. Association of PITX2 mRNA down-regulation in prostate cancer with promoter hypermethylation and poor prognosis. Urol Oncol 2013;31:622-7
75. Dietrich D, Hasinger O, Banez LL, et al. Development and clinical validation of a real-time PCR assay for PITX2 DNA methylation to predict prostate-specific antigen recurrence in prostate cancer patients following radical prostatectomy. J Mol Diagn 2013;15(2): 270-9
76. Kuzmin I, Liu L, Dammann R, et al. Inactivation of RAS Association Domain Family 1A gene in cervical carcinomas and the role of human papillomavirus infection. Cancer Res 2003;63:1888-93
77. Shigematsu H, Suzuki M, Takahashi T, et al. Aberrant methylation of HIN-1 (high in normal-1) is a frequent event in human malignancies. Int J Cancer 2005;113:600-4
78. Kim TY, Lee HJ, Hwang KS, et al. Methylation of RUNX3 in various types of human cancers and premalignant stages of gastric carcinoma. Lab Invest 2004;84: 479-84
79. Cho B, Lee H, Jeong SW, et al. Promoter hypomethylaton of a novel cancer/testis antigen gene CAGE is correlated with its aberrant expression and is seen in premalignant stage of gastric carcinoma. Biochem Biophys Res Commun 2003;307: 52-63
80. Shivapurkar N, Toyooka S, Toyooka KO, et al. Aberrant methylation of TRAIL decoy receptor genes is frequent in multiple tumor types. Intl J Cancer 2004;109:786-92
81. Liu H, Liu W, Wu Y, et al. Loss of epigenetic control of synuclein-g gene as a molecular indicator of metastasis in a wide range of human cancers. Cancer Res 2005;65:7635-43
82. Zhang Y, Bhat I, Zeng M, et al. Human kallikrein 10, a predictive marker for breast cancer. Biol Chem 2006;387(6):715-21
83. Haraldson K, Kashuba VI, Dmitriev AA, et al. LRRC3B gene is frequently epigenetically inactivated in several epithelial malignancies and inhibits cell growth and replication. Biochimie 2012;94:1151-7
84. Day TK, Bianco-Miotto T. Common gene pathways and families altered by DNA methylation in breast and prostate cancers. Endocr Relat Cancer 2013;20: R215-32
85. Graham TA, Humphries A, Sanders T, et al. Use of methylation patterns to determine expansion of stem cell clones in human colon tissue. Gastroenterology 2011;140:1241-50
86. Killian JK, Bilke S, Davis S, et al. Large-scale profiling of archival lymph nodes reveals pervasive remodeling of the follicular lymphoma methylome. Cancer Res 2009;69:758-64
87. Church TR, Wandell M, Lofton-Day C, et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut 2014; 63(2):317-25
88. Hesselink AT, Heideman DAM, Steenbergen RDM, et al. Methylation marker analysis of self-sampled cervicovaginal lavage specimens to triage high-risk HPV-positive women for colposcopy. Int J Cancer 2014. [Epub ahead of print]
89. Henrique R, Ribeiro FR, Fonseca D, et al. High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients. Clin Cancer Res 2007;13(20):6122-9